Arcturus Reports Positive Mid-Stage Trial Results for ARCT-810 in OTC Deficiency
Arcturus Therapeutics (ARCT) announced positive interim results from a phase 2 trial of its investigational drug, ARCT-810. The therapy demonstrated the ability to reduce and maintain morning fasting ammonia levels within normal ranges for patients with ornithine transcarbamylase deficiency, an inherited metabolic disorder. The treatment also showed reductions in glutamine levels among some participants, a key biomarker associated with OTC deficiency. These findings suggest potential therapeutic benefits that could improve the management of this rare disease and support further clinical development. Positive trial outcomes may enhance investor confidence in Arcturus' pipeline and reinforce its position as an innovator in RNA therapeutics for metabolic disorders.
Tickers: $ARCT
Topics: biotech drug_development rare_diseases